Elizalde GJJ

Language: English
References: 0
Page: 214-215
PDF size: 100.69 Kb.

ABSTRACT

Since the first reports from China at the beginning of the COVID-19 pandemic, a high frequency of thrombotic phenomena in different vascular territories was described in these patients, particularly at the pulmonary level, although also in the deep venous system of the lower limbs (DVT), brain and heart among others, reaching in some cases to meet criteria of disseminated intravascular coagulation.
SARS-CoV-2 usually produces a significant thrombo-inflammatory response in the severe pneumonic forms of COVID-19 with progressive diffuse lung damage. The endothelial cells (ECs) play a significant role in vasodilation control, thrombotic regulation, fibrinolysis and antiaggregation between other important functions; with hypercoagulable profiles associated with severe disease indicating significant active SARS-CoV-2 ECs injury and dysfunction that can last for months in survivors, not to mention the havoc produced on alveolar epithelial cells, that will most likely trigger interstitial lung disease of different magnitude in the medium and long term, which could hit humanity in the near future particularly hard with thousands of new cases of progressive pulmonary fibrosis.